# Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study

> **NCT00644540** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 89 (actual)

## Conditions studied

- FLU

## Interventions

- **BIOLOGICAL:** Influenza Trivalent Inactivated Vaccines
- **BIOLOGICAL:** Influenza Trivalent Inactivated Vaccines

## Key facts

- **NCT ID:** NCT00644540
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-01
- **Final completion:** 2008-06
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00644540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00644540, "Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00644540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*